

DT05 PCT/PTO 07 FEB 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Satoru Oht et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2005_0468A
Filed February 7, 2005 :

FUSED HETEROCYCLIC COMPOUNDS AS
PEPTIDASE INHIBITORS
[Corresponding to PCT/JP03/10054
Filed August 7, 2003]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO 1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application PCT/JP03/10054; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, or
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

10/523531

DT05 PCT/PTO 07 FEB 2005

- ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449 reference is made to:
- a. ☐ a full or partial English language translation submitted herewith;
 - b. ☒ a foreign patent office search report (in the English language) submitted herewith;
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed along with an International Preliminary Examination Report.

Respectfully submitted,

Satoru OI et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
February 7, 2005

Sheet 1 of 1		INFORMATION DISCLOSURE STATEMENT		<div style="display: flex; justify-content: space-between;"> DT05 Rec'd 10/523531 </div> <div style="display: flex; justify-content: space-between;"> CH/PTO 07 FEB 2005 </div>			
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) <i>(Use several sheets if necessary)</i> Date Submitted to PTO: February 7, 2005		ATTY DOCKET NO. 2005_0168A		SERIAL NO. 10/523531			
		APPLICANT Satoru Oi et al.					
		FILING DATE February 7, 2005		GROUP			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AJ	03/068748	8/2003	WO			
	AK	98/19998	5/1998	WO			
	AL	01/82925	11/2001	WO			Abstract
	AM	02/062764	8/2002	WO			
	AN						
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AO	G. M. Coppola et al., "1-Aminomethylisoquinoline-4-carboxylates as Novel Dipeptidylpeptidase IV Inhibitors", Bioorganic & Medicinal Chemistry Letters, Vol. 10, 2000, pp. 1555-1558.					
	AP	K. Augustyns et al., "The Unique Properties of Dipeptidyl-peptidase IV (DPP IV/CD26) and the Therapeutic Potential of DPP IV Inhibitors", Current Medicinal Chemistry, Vol. 6, 1999, pp. 311-327.					
	AQ						
EXAMINER				/Taofiq Solola/			
				DATE CONSIDERED 03/26/2008			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./